Compromiso cardiovascular secundario a tumor carcinoide metastásico

Autores/as

DOI:

https://doi.org/10.21615/cesmedicina.34.3.7

Palabras clave:

Cardiopatía carcinoide, Tumor carcinoide, Síndrome carcinoide maligno

Resumen

Los tumores carcinoides son neoplasias pertenecientes a la familia de tumores neuroendocrinos y presentan baja incidencia en la población en general; sin embargo, hasta el 50 % pueden debutar con compromiso cardiovascular. Se presenta el caso de un paciente, sin antecedentes cardiovasculares quien presentó signos y síntomas sugestivos de falla cardiaca derecha. Se le realizó ecocardiografía transtorácica que evidenció compromiso de ambas válvulas cardíacas derechas por tumor neuroendocrino metastásico, llevando al diagnóstico de sindrome carcinoide. Con el fin de tener presente dicha entidad en la práctica diaria de la cardiología clínica se revisan datos claves de abordaje diagnóstico y terapéutico.

Citas

Bhattacharyya S, Davar J, Dreyfus G, Caplin ME. Carcinoid Heart Disease. Circulation. 2007;116(24):2860-5.

Paredes A, Valdebenito M, Neira V, Castro P, Zalaquett R. Síndrome carcinoide y compromiso valvular cardíaco. Rev Chil Cardiol. 2014;33(1):38-43.

Davar J, Connolly HM, Caplin ME, Pavel M, Zacks J, Bhattacharyya S, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors. J Am Coll Cardiol. 2017;69(10):1288-304.

Shah PM. Valvulopatía tricuspídea y pulmonar: evaluación y tratamiento. Rev Esp Cardiol. 2010;63(11):1349-65.

Møller JE, Pellikka PA, Bernheim AM, Schaff HV, Rubin J, Connolly HM. Prognosis of carcinoid heart disease: analysis of 200 cases over two decades. Circulation. 2005;112(21):3320-7.

Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J, Yusuf SW. Carcinoid heart disease. Heart. 2017;103(19):1488-95.

Perry D, Hayek SS. Carcinoid Heart Disease. Cardiol Clin. 2019;37(4):497-503.

Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid Heart Disease. N Engl J Med. 2003;348(11):1005-15.

Simula DV, Edwards WD, Tazelaar HD, Connolly HM, Schaff HV. Surgical Pathology of Carcinoid Heart Disease: A Study of 139 Valves From 75 Patients Spanning 20 Years. Mayo Clin Proc. 2002;77(2):139-47.

Bhattacharyya S, Toumpanakis C, Burke M, Taylor AM, Caplin ME, Davar J. Features of carcinoid heart disease identified by 2- and 3-dimensional echocardiography and cardiac MRI. Circ Cardiovasc Imaging. 2010;3(1):103-11.

Maria Alegret J, Subirana MT, Marcuello E, Bayés-Genís A, Ferrés P, Torner M. Afectación valvular tricuspídea y pulmonar en un caso de síndrome carcinoide. Rev Esp Cardiol. 1997;50(7):532-4.

Connolly HM, Schaff HV, Mullany CJ, Rubin J, Abel MD, Pellikka PA. Surgical management of left-sided carcinoid heart disease. Circulation. 2001;104:I-36-I-40.

Fox DJ. Carcinoid heart disease: presentation, diagnosis, and management. Heart. 2004;90(10):1224-8.

Luis SA, Pellikka PA. Carcinoid heart disease: Diagnosis and management. Best Pract Res Clin Endocrinol Metab. 2016;30(1):149-58.

Korse CM, Taal BG, de Groot CA, Bakker RH, Bonfrer JMG. Chromogranin-A and N-Terminal pro-brain natriuretic peptide: an excellent pair of biomarkers for diagnostics in patients with neuroendocrine tumor. J Clin Oncol. 2009;27(26):4293-9.

Bhattacharyya S, Toumpanakis C, Chilkunda D, Caplin ME, Davar J. Risk Factors for the Development and Progression of Carcinoid Heart Disease. Am J Cardiol. 2011;107(8):1221-6.

Zuetenhorst JM, Bonfrer JMGM, Korse CM, Bakker R, van Tinteren H, Taal BG. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-Beta and fibroblast growth factor. Cancer 2003;97(7):1609-15.

Pandya UH, Pellikka PA, Enriquez-Sarano M, Edwards WD, Schaff HV, Connolly HM. Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients. J Am Coll Cardiol. 2002;40(7):1328-32.

Matshela MR. Cases in a series of carcinoid syndrome and carcinoid heart disease. Cardiovasc J Afr. 13 de septiembre de 2018;29(4):e1-7.

Ferrari A, Glasberg J, Riechelmann R. Carcinoid syndrome: update on the pathophysiology and treatment. Clinics 2018;73.

Steeds RP, Sagar V, Shetty S, Oelofse T, Singh H, Ahmad R, et al. Multidisciplinary team management of carcinoid heart disease. Endocr Connect. 2019;8(12):R184-99.

Lillegard JB, Fisher JE, Mckenzie TJ, Que FG, Farnell MB, Kendrick ML, et al. Hepatic Resection for the carcinoid syndrome in patients with severe carcinoid heart disease: does valve replacement permit safe hepatic resection? J Am Coll Surg. 2011;213(1):130-6.

Mujtaba SS, Clark S. Carcinoid Heart Disease: Early outcomes after surgical valve replacement in nine patients. Heart Surg Forum. 16 de febrero de 2018;21(1):040.

Bonou M, Kapelios CJ, Kaltsas G, Perreas K, Toutouzas K, Barbetseas J. Cardiac Surgery for carcinoid heart disease: a weapon not to be misused. Cardiology. 2017;136(4):243-51.

Mujtaba SS, Clark S. Quadruple Valve replacement for carcinoid heart disease. Braz J Cardiovasc Surg. 2018;33(4).

Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK. Transcatheter pulmonic valve replacement in carcinoid heart disease. Eur Heart J - Cardiovasc Imaging. 2015.

Descargas

Publicado

2020-12-09

Cómo citar

Mejía Zuluaga, M., Bedoya Jaramillo, T. M., Duarte Suárez, N. R., Naranjo Restrepo, S., & Duque Ramírez, M. (2020). Compromiso cardiovascular secundario a tumor carcinoide metastásico. CES Medicina, 34(3), 228-235. https://doi.org/10.21615/cesmedicina.34.3.7

Número

Sección

Reporte de caso